<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01090596</url>
  </required_header>
  <id_info>
    <org_study_id>ResearchANY</org_study_id>
    <nct_id>NCT01090596</nct_id>
  </id_info>
  <brief_title>Changes in mRNA Expression Following Exposure to Naproxen</brief_title>
  <acronym>Lesions3</acronym>
  <official_title>Changes in mRNA Expression Following Exposure to Naproxen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Research Associates of New York, LLP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Research Associates of New York, LLP</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using tissue samples obtained from a previous study, the effect of naproxen on the gene
      expression profiles of antral mucosal tissue will be assessed. We hypothesize that there will
      be distinct changes in the gene expression profiles of samples taken from individuals treated
      with naproxen versus samples taken from individuals treated with placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will use microarray technology to quantify the transcriptome-wide changes in gene
      expression in said-samples.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fold Change in Gene Expression</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Naproxen-Treated</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>500mg naproxen, twice daily for 7 days</description>
    <arm_group_label>Naproxen-Treated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tab,twice a day for a seven days</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult between the ages of 18 and 75 inclusive

          -  Written informed consent prior to undergoing any study procedures

          -  A physical examination which reveals no clinically significant abnormalities

          -  Female subjects of childbearing potential must be taking an acceptable form of
             contraceptive

        Exclusion Criteria:

          -  Any mucosal breaks within 2 cm of pyloric channel seen on baseline endoscopy

          -  Any GDU or &gt;5 gastroduodenal erosions at baseline endoscopy

          -  CXB, CPG, ASA, or NS-NSAID use within the prior 2 weeks

          -  Previous gastrointestinal ulcer

          -  Hypersensitivity or allergy to NSAIDs, ASA, CPG, CXB or other contraindication to
             taking treatments

          -  Baseline complaints of abdominal pain, nausea, and/or cramping

          -  Any acid blocking medication including antacids, H-2 receptor blocker within the prior
             2 weeks, or PPI use within the prior 30 days

          -  Corticosteroids use within the prior 60 days

          -  Any documented bleeding tendency

          -  Has taken warfarin within the prior 60 days

          -  Three or greater alcoholic beverages daily

          -  History of cerebro-vascular event
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Aisenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Associates of New York</affiliation>
  </overall_official>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2010</study_first_submitted>
  <study_first_submitted_qc>March 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2010</study_first_posted>
  <last_update_submitted>March 18, 2010</last_update_submitted>
  <last_update_submitted_qc>March 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>James Aisenberg, MD</name_title>
    <organization>Research Associates of New York</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

